Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Jacobson Mark L.	2. Date of Event Requiring Statement (MM/DD/YYYY) 2/28/2020	3. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM]
(Last)        (First)        (Middle) C/O AXSOME THERAPEUTICS, INC., 200 BROADWAY, 3RD FLOOR	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Operating Officer /
(Street) NEW YORK, NY 10038       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	4/2/2024	Common Stock	24662	$1.30	D
Stock Option (Right to Buy)	(2)	6/17/2024	Common Stock	19862	$1.30	D
Stock Option (Right to Buy)	(1)	12/28/2024	Common Stock	47739	$4.04	D
Stock Option (Right to Buy)	(1)	9/14/2025	Common Stock	40673	$6.47	D
Stock Option (Right to Buy)	(3)	5/26/2026	Common Stock	25000	$8.02	D
Stock Option (Right to Buy)	(4)	3/14/2027	Common Stock	25000	$4.95	D
Stock Option (Right to Buy)	(5)	9/12/2027	Common Stock	15000	$4.85	D
Stock Option (Right to Buy)	(6)	3/11/2028	Common Stock	45378	$2.85	D
Stock Option (Right to Buy)	(7)	3/19/2029	Common Stock	119704	$12.95	D
Stock Option (Right to Buy)	(8)	10/10/2029	Common Stock	25813	$17.61	D

Explanation of Responses:
(1)	The option is exercisable immediately.
(2)	6,169 options will vest upon the achievement of certain performance based milestones and the remainder of the option is exercisable immediately.
(3)	The option was granted on May 27, 2016, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested.
(4)	The option was granted on March 15, 2017, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested.
(5)	The option was granted on September 13, 2017, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested.
(6)	The option was granted on March 12, 2018, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested.
(7)	The option was granted on March 19, 2019, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested.
(8)	The option was granted on October 10, 2019. Fifty percent (50%) of the option is exercisable immediately as of the date of grant with the remaining fifty percent (50%) to vest in equal increments on a quarterly basis over a four (4) year period.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Jacobson Mark L. C/O AXSOME THERAPEUTICS, INC. 200 BROADWAY, 3RD FLOOR NEW YORK, NY 10038			Chief Operating Officer

Signatures
/s/ Mark Jacobson		3/9/2020
**Signature of Reporting Person		Date